Page last updated: 2024-09-04

cryptotanshinone and Urinary Bladder Neoplasms

cryptotanshinone has been researched along with Urinary Bladder Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Inoue, H; Kageyama, S; Kawauchi, A; Kim, CJ; Mukaisho, KI; Tambe, Y; Terado, T	1

Other Studies

1 other study(ies) available for cryptotanshinone and Urinary Bladder Neoplasms

Article	Year
Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR/β‑catenin/N‑cadherin axis. International journal of oncology, 2021, Volume: 59, Issue:1 Topics: Animals; Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Cell Line, Tumor; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenanthrenes; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Signal Transduction; Spheroids, Cellular; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2021

Article

Year

Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR/β‑catenin/N‑cadherin axis.

International journal of oncology, 2021, Volume: 59, Issue:1

Topics: Animals; Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Cell Line, Tumor; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenanthrenes; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Signal Transduction; Spheroids, Cellular; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2021